US20170119710A1 - Treatment of conditions related to shock - Google Patents
Treatment of conditions related to shock Download PDFInfo
- Publication number
- US20170119710A1 US20170119710A1 US15/404,002 US201715404002A US2017119710A1 US 20170119710 A1 US20170119710 A1 US 20170119710A1 US 201715404002 A US201715404002 A US 201715404002A US 2017119710 A1 US2017119710 A1 US 2017119710A1
- Authority
- US
- United States
- Prior art keywords
- shock
- inhibitor
- intestine
- treatment
- serine protease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000035939 shock Effects 0.000 title abstract description 72
- 238000011282 treatment Methods 0.000 title abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 47
- 210000000936 intestine Anatomy 0.000 claims description 56
- 102000038379 digestive enzymes Human genes 0.000 claims description 43
- 108091007734 digestive enzymes Proteins 0.000 claims description 43
- 206010040070 Septic Shock Diseases 0.000 claims description 20
- 239000002532 enzyme inhibitor Substances 0.000 claims description 20
- 229940125532 enzyme inhibitor Drugs 0.000 claims description 19
- 230000036303 septic shock Effects 0.000 claims description 19
- 108010039627 Aprotinin Proteins 0.000 claims description 16
- 239000003001 serine protease inhibitor Substances 0.000 claims description 16
- 229940122055 Serine protease inhibitor Drugs 0.000 claims description 15
- 101710102218 Serine protease inhibitor Proteins 0.000 claims description 15
- 231100000433 cytotoxic Toxicity 0.000 claims description 14
- 230000001472 cytotoxic effect Effects 0.000 claims description 14
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 13
- 229960004405 aprotinin Drugs 0.000 claims description 12
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims description 12
- 229960000401 tranexamic acid Drugs 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 9
- 210000004303 peritoneum Anatomy 0.000 claims description 8
- 229940086609 Lipase inhibitor Drugs 0.000 claims description 7
- 229950009865 nafamostat Drugs 0.000 claims description 7
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 7
- 229960001243 orlistat Drugs 0.000 claims description 7
- 238000011287 therapeutic dose Methods 0.000 claims description 7
- -1 6-amidino-2-naphthyl Chemical group 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 229960003722 doxycycline Drugs 0.000 claims description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 4
- 229940124761 MMP inhibitor Drugs 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 210000003200 peritoneal cavity Anatomy 0.000 claims description 3
- MQQNFDZXWVTQEH-UHFFFAOYSA-N nafamostat Chemical group C1=CC(N=C(N)N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C(N)=N)C2=C1 MQQNFDZXWVTQEH-UHFFFAOYSA-N 0.000 claims 5
- 230000005764 inhibitory process Effects 0.000 abstract description 17
- 230000002265 prevention Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 description 28
- 102000035195 Peptidases Human genes 0.000 description 24
- 108091005804 Peptidases Proteins 0.000 description 24
- 239000004365 Protease Substances 0.000 description 23
- 208000034486 Multi-organ failure Diseases 0.000 description 22
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 22
- 230000004054 inflammatory process Effects 0.000 description 19
- 206010061218 Inflammation Diseases 0.000 description 18
- 235000019419 proteases Nutrition 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 230000002757 inflammatory effect Effects 0.000 description 16
- 238000001356 surgical procedure Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 10
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 9
- 206010049771 Shock haemorrhagic Diseases 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000004087 circulation Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 235000021588 free fatty acids Nutrition 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000004089 microcirculation Effects 0.000 description 8
- 230000010410 reperfusion Effects 0.000 description 8
- 230000030833 cell death Effects 0.000 description 7
- 238000002695 general anesthesia Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 102000003746 Insulin Receptor Human genes 0.000 description 6
- 108010001127 Insulin Receptor Proteins 0.000 description 6
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- 206010040047 Sepsis Diseases 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 108091007735 digestive proteases Proteins 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 102100027211 Albumin Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 102000019280 Pancreatic lipases Human genes 0.000 description 4
- 108050006759 Pancreatic lipases Proteins 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 4
- 238000002283 elective surgery Methods 0.000 description 4
- 230000006862 enzymatic digestion Effects 0.000 description 4
- 208000037817 intestinal injury Diseases 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 229940108519 trasylol Drugs 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 3
- 206010022680 Intestinal ischaemia Diseases 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- ZPNFWUPYTFPOJU-MPSLMFKFSA-N aprotinin Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]2CSSC[C@H]3NC(=O)CNC(=O)CNC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CSSC[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc4ccccc4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](CSSC[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](CC(O)=O)NC(=O)[C@H]3CCCN3C(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N3CCC[C@@H]3C(=O)N3CCC[C@H]3C(=O)N[C@H](Cc3ccc(O)cc3)C(=O)N[C@H]([C@H](C)O)C(=O)NCC(=O)N3CCC[C@H]3C(=O)N2)C(=O)NCC(=O)NCC(=O)N[C@H](C)C(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](NC1=O)[C@H](C)CC)[C@@H](C)O)C(C)C ZPNFWUPYTFPOJU-MPSLMFKFSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 239000003145 cytotoxic factor Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 229950000501 gabexate Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000003960 inflammatory cascade Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 235000019626 lipase activity Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000006240 membrane receptors Human genes 0.000 description 3
- 108020004084 membrane receptors Proteins 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000264 venule Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- GGKNTGJPGZQNID-UHFFFAOYSA-N (1-$l^{1}-oxidanyl-2,2,6,6-tetramethylpiperidin-4-yl)-trimethylazanium Chemical compound CC1(C)CC([N+](C)(C)C)CC(C)(C)N1[O] GGKNTGJPGZQNID-UHFFFAOYSA-N 0.000 description 2
- 101710194905 ARF GTPase-activating protein GIT1 Proteins 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100029217 High affinity cationic amino acid transporter 1 Human genes 0.000 description 2
- 101710081758 High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 231100000284 endotoxic Toxicity 0.000 description 2
- 230000002346 endotoxic effect Effects 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002682 general surgery Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006377 glucose transport Effects 0.000 description 2
- 229940056944 golytely Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 229940040461 lipase Drugs 0.000 description 2
- 102000019758 lipid binding proteins Human genes 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 230000004768 organ dysfunction Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- NCCJWSXETVVUHK-ZYSAIPPVSA-N (z)-7-[(2r)-2-amino-2-carboxyethyl]sulfanyl-2-[[(1s)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid;(5r,6s)-3-[2-(aminomethylideneamino)ethylsulfanyl]-6-[(1r)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C1C(SCC\N=C/N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21.CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O NCCJWSXETVVUHK-ZYSAIPPVSA-N 0.000 description 1
- 101710129138 ATP synthase subunit 9, mitochondrial Proteins 0.000 description 1
- 101710168506 ATP synthase subunit C, plastid Proteins 0.000 description 1
- 101710114069 ATP synthase subunit c Proteins 0.000 description 1
- 101710197943 ATP synthase subunit c, chloroplastic Proteins 0.000 description 1
- 101710187091 ATP synthase subunit c, sodium ion specific Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010017982 Gastrointestinal necrosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 102000005393 Sodium-Potassium-Exchanging ATPase Human genes 0.000 description 1
- 108010006431 Sodium-Potassium-Exchanging ATPase Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000025911 acute intestinal ischemia Diseases 0.000 description 1
- 201000006781 acute vascular insufficiency of intestine Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 229940099355 cyklokapron Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229960000209 drotrecogin alfa (activated) Drugs 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 235000019138 food restriction Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000000122 hyperventilation Diseases 0.000 description 1
- 230000000870 hyperventilation Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 108091016323 lipid binding proteins Proteins 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001363 mesenteric artery superior Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004677 mucosal permeability Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000009184 walking Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- the present invention relates to treatment of shock.
- the present invention relates to treatment of conditions related to shock.
- Shock is a life-threatening complication in situations associated with trauma including burns, surgery, ischemia, sepsis, and other critical care applications. Shock is a broad term that describes a group of circulatory syndromes, all of which result in general cellular hypoxia. This leads to a depletion of the adenosine triphosphate (ATP), the failure of the sodium-potassium pump, mitochondrial dysfunction, and ultimately the release of a variety of toxic substances, including superoxides. Superoxides are toxic to essentially all tissues. They react with proteins and cause unfolding and are able to induce DNA damage.
- ATP adenosine triphosphate
- cellular activation in the circulation can be detected by leukocytes or endothelial cells resulting in superoxide production, pseudopod projections, enzyme release, cytokine release, and expression of membrane adhesion molecules.
- Cell activation fundamentally alters the biomechanics of microvascular blood flow by a shift in rheological, adhesive, and cytotoxic cell properties. Eventually these stress responses give rise to irreversible cardiovascular collapse because of their combined effects on the microcirculation.
- the treatment should be simple to administer, effective and capable of aiding in emergency situations.
- the present invention is a technique for treatment of conditions related to physiological shock by administering a more specific combination of therapeutic agents, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described methods, for example, that in U.S. Pat. No. 6,534,283, which is incorporated by reference herein in its entirety.
- the present invention is based upon a new hypothesis for the cause of shock and multi-organ failure: self-digestion through gut ischemic complications rather than bacterial/endotoxin invasion.
- the present invention dramatically reduces symptoms of multi-organ failure and mortality in septic shock associated with leakage of cecal material into the peritoneum (e.g., cecal ligation shock). Furthermore, the present invention reduces symptoms of insulin resistance in shock (e.g., septic, hemorrhagic and cecal ligation shock). The methods were tested and verified in various animal studies as discussed below.
- the present invention is a method for prevention or treatment of physiological shock.
- the method includes administering to a peritoneum of an individual a therapeutic dose of any combination of one or more of: pancreatic digestive enzyme inhibitor, cytotoxic mediator inhibitor, and antibacterial agent.
- a method according to the present invention blocks formation of inflammatory mediators by pancreatic digestive enzymes in the intestine in septic shock and thereby reduces symptoms of multi-organ failure and significantly reduces mortality rate. It also serves to reduce morbidity and reduce post-operative complications, enhance recovery rate, and shorten hospital stays.
- the treatment is administered into the lumen of the intestine to block fully activated digestive enzymes and auto-digestion of the intestine.
- the treatment is highly effective to attenuate prolonged formation of inflammation in septic shock, destruction of the intestinal epithelial lining, and reduces mortality. There is currently no comparable treatment for septic shock.
- This invention describes techniques for treatment of conditions related to shock.
- Various exemplary embodiments are presented to provide a broad spectrum of treatment available and application to such conditions.
- treatment is administered into the lumen of the intestine in combination with a treatment of the peritoneal cavity that can be administered after onset of shock.
- the inventors discovered that delayed inhibition of digestive enzymes in the lumen of the intestine reduces inflammatory markers after shock.
- the inventors examined the effectiveness of a delayed intestinal protease inhibition during reperfusion after SMAO.
- Male Wistar rats were exposed to superior mesenteric artery occlusion (SMAO) for 100 min and treated by delayed intestinal lavage beginning 40 min after reperfusion with either buffer or a reversible digestive protease inhibitor (FOY, 0.37 mM). Arterial pressure during reperfusion was significantly lower in shock animals compared with sham shock animals.
- SMAO superior mesenteric artery occlusion
- SMAO and reperfusion without protease blockade caused the formation of leukocyte activation factors in intestinal homogenates and in plasma, as well as intestinal injury and also caused a significant increase in activated leukocytes in venules of cremaster muscle.
- delayed lavage at 40 min after reperfusion led to a highly significant restoration of the initial blood pressure before shock, decreased formation of intestine-derived leukocyte activation factors and intestinal injury.
- Delayed digestive enzyme blockade also caused lower leukocytes adhesion in post-capillary venules and reduced cell death in the cremaster muscle microcirculation. Intestinal ischemia-induced endotoxemia was prevented by digestive enzyme inhibition.
- delayed intestinal protease inhibition serves to improve experimental SMAO-induced shock by reducing intestinal injury, the level of cell activation in plasma and in the microcirculation, and by restoring the blood pressure.
- Both treated pigs (6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate (ANGD), 100 ml/kg of 0.37 mM in GOLYTELY, PEG-3350 and electrolytes for oral solution, via a duodenal catheter at 1 liter/hr directly into the lumen of the intestine) and controls (GOLYTELY, PEG-3350 and electrolytes for oral solution, only) had significant reductions in protein and protease levels in the duodenum during enteroclysis, however only ANGD treated animals had persistent suppression of protease activity in the intestinal lumen and in plasma throughout the experiment.
- a digestive enzyme inhibitor given via enteroclysis significantly reduces leukocyte activation and transfusion requirements during resuscitation from hemorrhagic shock.
- intra-intestinal pancreatic protease inhibition results in a stable blood pressure throughout the experiment.
- Cell activation and leukocyte-endothelial interactions both in term of rolling and firm adhesion to the endothelium and cell death (as measured by propidium iodine labeling) in the cremaster muscle, were almost completely abolished after blockade with gabexate mesilate.
- ischemia-induced intestinal mucosal injury is attenuated with intestinal pancreatic protease inhibition.
- intestinal pancreatic protease inhibition significantly attenuates intestinal ischemia-induced shock by reducing the systemic inflammatory response syndrome.
- digestive enzyme blockade is protective against inflammation in shock if placed inside the lumen of the intestine and less by intravenous administration.
- an important feature is the fact that the significant protection rendered by the inhibition of pancreatic digestive enzymes is only provided if the enzymes are blocked inside the lumen of the intestine. If the enzyme inhibitors are administered directly into the circulation (ib., i.a., i.m.), less, and in some cases no protection is achieved, a feature that has been confirmed using different protease inhibitors (ANGD and aprotinin).
- pancreatic digestive enzymes mediate microvascular inflammation in septic shock. Sepsis is accompanied by severe inflammation whose mechanism remains uncertain.
- the inventors examined the possibility that pancreatic digestive enzymes may also be involved in inflammation in an experimental form of septic shock with a lethal dose of endotoxin in the rat.
- endotoxin administration 4 mg/kg, gram-negative
- control rats developed hypotension, tachycardia, hyperventilation and leukopenia.
- the intestine and plasma contained mediators that activated leukocytes.
- the leukocyte-endothelial interaction within the cremaster muscle microcirculation was enhanced.
- Endotoxin administration resulted in elevated IL-6 plasma levels and histological evidence indicates liver and intestinal injury.
- blockade of pancreatic proteases in the intestinal lumen significantly improved hemodynamic parameters and reduces all indices of inflammation in plasma as well as cell injury in peripheral skeletal muscle microcirculation.
- endotoxic shock the rats received gram-negative endotoxin (5 mg/kg, ib.); the digestive enzymes were blocked in the same way at 1 hour after endotoxin administration. No other agent was administered.
- cecal ligation shock both the digestive enzymes in the lumen of the intestine as well as inside the peritoneum were blocked with ANGD.
- Untreated controls in each model of shock had high mortality (within less than 8 hours), while blockade of the digestive enzymes ANGD in each shock model lead to a significantly enhanced survival rate (Table I).
- untreated controls all treated survivors returned after anesthesia within hours to normal activity (walking, climbing, grooming, drinking, eating, bowel movements) and within 3 days to normal weight gain.
- shock rats has protease activity and causes cleavage of the extracellular domain of the insulin receptor, E-cadherin, and CAT-1.
- the inventors investigated the ability of central venous plasma of rats in hemorrhagic shock (collected at 4 hours) to cleave the extracellular domain of the insulin receptor a by using an antibody against the extracellular binding domain of insulin combined with membrane receptor density measurements. Exposure of normal donor cells to plasma from shock rats, but not to plasma of control rats, causes extensive cleavage of the insulin binding domain. Furthermore, this cleavage causes also a reduction of the glucose transport into the cell cytoplasm.
- pancreatic enzymes generate cytotoxic mediators in the intestine. And, thus, there exists a link between the permeability increase in the intestinal wall and the early stages of shock with formation of inflammatory and cytotoxic factors. These factors may either be already present in form of digested food or may be created by action of digestive enzymes on interstitial structures after entry into the intestinal wall and may cause the intestinal necrosis observed in shock.
- both individual serine proteases and fluid from the lumen of the intestine with endogenous proteases have the ability to generate cytotoxicity from intestinal wall homogenates and that luminal fluid may also generate cytotoxicity from homogenized food.
- the inventors sought to show that the intestine is a source of cytotoxic mediators in shock, and the role of free fatty acids and degradation of lipid-binding proteins.
- the inventors showed that using chloroform/methanol separation of rat small intestine homogenates into lipid fractions and aqueous and sedimented protein fractions and measuring cell death caused by those fractions, it was found that the cytotoxic factors are lipid in nature. Recombining the lipid fraction with protein fractions prevented cell death, except when homogenates were protease digested.
- a fluorescent substrate Using a fluorescent substrate, the inventors found high levels of lipase activity in intestinal homogenates and cytotoxic levels of free fatty acids. Addition of albumin, a lipid binding protein, prevented cell death, unless the albumin was previously digested with protease. Homogenization of intestinal wall in the presence of the lipase inhibitor orlistat prevented cell death after protease digestion. In vivo, orlistat plus the protease inhibitor aprotinin, administered to the intestinal lumen, significantly improved survival time compared with saline in a splanchnic arterial occlusion model of shock. These results indicate that major cytotoxic mediators derived from an intestine under in vitro conditions are free fatty acids (FFAs). Breakdown of free fatty acid binding proteins by proteases causes release of free fatty acids to act as powerful cytotoxic mediators.
- FFAs free fatty acids
- the discovery further includes clarification of the mechanism that leads to insulin resistance. It is shown that one of the ways that the present invention works is due to enzymatic cleavage of the insulin binding-domain, and introduction of proteases attenuates the process.
- Matrix metalloproteinase (MMP)-9) protein showed enhanced levels in SHR microvessels, mast cells, and leukocytes compared with normotensive Wistar-Kyoto rats.
- MMP-1 and -9 in SHRs that colocalizes with MMP-9 and is blocked by metal chelation.
- SHR plasma also has enhanced protease activity.
- the inventors demonstrated with an antibody against the extracellular domain that the insulin receptor- ⁇ density is reduced in SHRs, in line with elevated blood glucose levels and glycohemoglobin.
- Blockade of MMPs with a broad-acting inhibitor reduces protease activity in plasma and microvessels; blocks the proteolytic cleavage of the insulin receptor, the reduced glucose transport; normalizes blood glucose levels and glycohemoglobin levels; and reduces blood pressure and enhanced microvascular oxidative stress of SHRs.
- a broad-acting inhibitor dioxycycline, 5.4 mg/kg per day
- Treatment of septic shock is based on supportive care by treating the underlying infection (appropriate antibiotics within the first 4-8 hours of presentation) and on restoring tissue perfusion with a combination of fluid resuscitation (e.g., albumin, lactated or hypertonic saline) and vasopressor administration (e.g., noreinephrine).
- fluid resuscitation e.g., albumin, lactated or hypertonic saline
- vasopressor administration e.g., noreinephrine
- the present invention involves several components, which may be performed independently or in combination.
- One component of a treatment according to the present invention includes administration of a pancreatic enzyme inhibitor directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery, etc.).
- the agents to be used individually or in combination include but are not limited to: FUTHAN, nafamostat mesilate (0.37 mM); TRASYLOL, aprotinin (Aprotinin, Bayer) (1.4 mg/ml), serine protease inhibitor; CYKLOKAPRON, tranexamic acid (Pfizer) (1.4 mg/ml), serine protease inhibitor; broad based MMP inhibitors (e.g., doxycycline); orlistat (5 to 50 mg/ml), lipase inhibitor; plus any other pancreatic enzyme inhibitor.
- the amount administered may be adjusted according to intestine size and enzyme levels to achieve complete blockade of digestive enzyme activity.
- a second component of a treatment according to the present invention includes treatment of the peritoneum by a combination of three protective interventions: blockade of pancreatic digestive enzymes (serine proteases, lipases, as outlined in the first component described above); blockade of cytotoxic lipid derived mediators (e.g., free fatty acids) with free fatty acid binding proteins (e.g., albumin, and others); antibacterial treatment against gram-positive and gram-negative bacteria that have entered into the peritoneal space (with antibiotic treatment, e.g., ciprofloxacin, metronidazole, imipenem and cilastatin, ticarcillin and clavulanate, cefuroxime). Further effectiveness of the treatment is achieved by peritoneal/intraintestinal lavage in combination with the treatments listed above.
- pancreatic digestive enzymes serine proteases, lipases, as outlined in the first component described above
- blockade of cytotoxic lipid derived mediators e.g
- the administration of the serine proteases and MMPs with broad spectrum blockers, as outlined in the first component described above, may be alternatively or additionally performed through an intravenous (ib.) route.
- the present invention may be used in numerous medical treatments, including but not limited to, treatment for prevention of multi-organ failure and mortality in septic shock.
- Any lipase inhibitor in combination with a pancreatic or leukocyte derived protease inhibitor may have utility to prevent inflammation in septic shock.
- pancreatic protease inhibition is initiated to reduce complications and hospital stay after trauma/surgery.
- pancreatic enzymes in the intestine have the ability to generate powerful inflammatory mediators and that blockade of pancreatic enzymes in the lumen of the intestine attenuates inflammatory symptoms after different shock models.
- the present invention allows a reduction in inflammatory symptoms and complications (swelling, embolism formation, selected organ dysfunction, pulmonary embolism, incidence of stroke, patient mobility, morbidity, multi-organ failure, mortality) in any form of elective surgery/general anesthesia associated with elevated risks (such as prolonged surgery procedures, surgery with bypass requirements, surgery on patients with preconditions and risk factors, surgery involving the intestine and pancreas).
- inflammatory symptoms and complications swelling, embolism formation, selected organ dysfunction, pulmonary embolism, incidence of stroke, patient mobility, morbidity, multi-organ failure, mortality
- risk factors such as prolonged surgery procedures, surgery with bypass requirements, surgery on patients with preconditions and risk factors, surgery involving the intestine and pancreas.
- pancreatic enzyme inhibitor may be conducted directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery).
- the agents to be used are individually or in combination: Futhane (0.1 mM); Trasylol (Aprotinin, Bayer) (1.4 mg/ml), serine protease inhibitor; cyclokapron (Pfizer) (1.4 mg/ml), serine protease inhibitor; Orlestat (5 to 50 mg/ml), lipase inhibitor plus any other pancreatic enzyme inhibitor.
- the amount administered is adjusted according to intestine size to achieve complete blockade of digestive enzyme activity.
- the inhibitor is administered prior to general anesthesia/surgery as pretreatment.
- Blockade of digestive enzymes prior to general anesthesia may serve to preserve barrier properties of the intestinal mucosa, reduce inflammation in the central circulation, and consequently reduce recovery and wound healing periods, post-surgical complications, hospital stays, etc.
- a potentially useful application of the digestive enzyme inhibition as pre-treatment is for patients subjected to radiation or chemotherapeutic treatment. It could also work for radiation treatment under other circumstances to reduce symptoms of multi-organ failure.
- the present invention provides a method for pancreatic protease inhibition in septic shock.
- this embodiment includes but not limited to, treatment for prevention of multi-organ failure and mortality in septic shock.
- treatment for prevention of multi-organ failure and mortality in septic shock works by blocking formation of inflammatory mediators by pancreatic digestive enzymes in the intestine in septic shock and thereby reducing symptoms of multi-organ failure and mortality.
- the treatment is administered into the lumen of the intestine to block fully activated digestive enzymes and auto-digestion of the intestine.
- the treatment is highly effective to attenuate prolonged formation of inflammation in septic shock, destruction of the intestinal epithelial lining, and reduces mortality.
- pancreatic enzymes in the lumen of the intestine attenuates inflammatory symptoms after administration of a lethal dose of endotoxin (6 mg/kg).
- endotoxin 6 mg/kg
- a pancreatic enzyme inhibitor may be conducted directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery).
- the agents to be used are individually or in combination: FUTHAN, nafamostat mesilate (0.1 mM); TRASYLOL, aprotinin (1.4 mg/ml), serine protease inhibitor; orlistat (5 to 50 mg/ml), lipase inhibitor; plus any other pancreatic enzyme inhibitor.
- the amount administered is adjusted according to intestine size to achieve complete blockade of digestive enzyme activity.
- the present invention is used for pancreatic lipase inhibition to reduce mortality after shock.
- This embodiment is very useful for developing treatment for prevention of multi-organ failure and mortality in hemorrhagic shock, preventive treatment to reduce the probability for development of multi-organ failure in elective surgery, long-term treatment to reduce production of lipid derived inflammatory mediators associated in chronic diseases. It is also particularly useful because there does not appear to be any treatment proposed to attenuate inflammation by blockade of lipase activity in the intestine in either acute or chronic inflammatory conditions.
- This embodiment is designed as an intervention to block the lipase activity in the lumen of the intestine and also in the general circulation in those cases in which lipase enters from the lumen of the intestine into the circulation. This prevents formation of lipid derived inflammatory or cytotoxic mediators in shock and other inflammatory diseases and attenuate multi-organ failure in shock and chronic inflammation in diseases like hypertension, diabetes, the metabolic syndrome, cancers and in chronic degenerative diseases.
- pancreatic lipases lipid splitting enzymes. Blockade of pancreatic lipase serves to reduce mortality during shock and reduce inflammation that leads to multi-organ failure. Blockade of pancreatic lipase prior to general anesthesia may serve to preserve barrier properties of the intestinal mucosa, reduce inflammation in the central circulation, and consequently reduce recovery and wound healing periods, post-surgical complications, hospital stays, etc.
- the inventors have shown that the ischemic intestine produces a powerful set of lipid derived cytotoxic mediators and that the blockade of lipase in the intestine under in-vitro conditions blocks the production of lipid-derived cytotoxic mediators.
- pancreatic enzyme inhibitor directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery) may have a positive effect on recovery.
- the agents to be used are individually or in combination: orlistat (5 to 50 mg/ml), lipase inhibitor; plus any other pancreatic enzyme inhibitor.
- the amount administered is adjusted according to intestine size and content to achieve complete blockade of digestive enzyme activity.
- the inhibitor is administered after trauma or sepsis associated with risk for shock and multi-organ failure.
- pretreatment the inhibitor is administered prior to general anesthesia/surgery.
- the present invention is based on data from animal studies that show dramatic reduction in life-threatening shock by inhibiting a body's own aggressive digestive enzymes. This novel approach targets trigger mechanisms in auto-digestion before it launches lethal inflammatory cascade.
- the invention provides evidence from recent animal studies that for the first time, studies showed that blockade of the digestive enzymes during shock leads to long-term survival. The results show a dramatic reduction of mortality in hemorrhagic shock induced multi-organ failure. This treatment holds great promise for future clinical application, particularly in emergency rooms and before high-risk surgeries.
- a person is in shock, his or her life is on the line. The patient's survival may be in jeopardy not just that day, but within an hour because healthy organs can fail and die in rapid succession.
- the present invention is based on the latest research using rodent models of human hemorrhagic shock.
- the sudden lowering of blood pressure that occurs in people suffering from stroke can provoke the body's digestive enzymes to break down the body's own intestinal tissue as if it were food.
- Such enzymes' abnormal actions may be defined as “auto-digestion.”
- Auto-digestion is dangerous because not only does it injure healthy tissue but also contributes to multi-organ failure, which can be fatal.
- the healthy cells of the animals' intestinal tissue react to auto-digestion by releasing a slew of substances that can be toxic to the heart and other body organs. These substances, termed cytotoxic mediators, can reach these body organs via the blood stream.
- shock was induced in 19 lab rodents, all of which were then treated with therapies that mirror the emergency room care given to many human patients who suffer shock, which typically occurs when blood flow to the heart, lungs and other body organs is slowed as a result of trauma, dehydration, heart attack or stroke.
- inflammatory is the body's mechanism to repair, to heal tissue. But in shock, the inflammation never stops. It is out of control. Normally the body senses when the inflammatory process has completed its job and brings it to a halt.
- the specification may have presented the method and/or process of the present invention as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. As one of ordinary skill in the art would appreciate, other sequences of steps may be possible. Therefore, the particular order of the steps set forth in the specification should not be construed as limitations on the claims. In addition, the claims directed to the method and/or process of the present invention should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques.
Description
- This application is a continuation of U.S. Ser. No. 15/010,058, filed Jan. 29, 2016, now pending, which is a divisional of U.S. Ser. No. 12/681,510, filed Aug. 9, 2010, now issued as U.S. Pat. No. 9,272,034, which is a U.S. national stage application under 35 U.S.C. 371 of International application No. PCT/US2008/011529, filed Oct. 6, 2008, which claims priority to U.S. Provisional Patent Application Ser. No. 60/977,587, filed Oct. 4, 2007, and to U.S. Provisional Patent Application Ser. No. 60/980,430, filed Oct. 16, 2007, the contents of all of which are hereby incorporated by reference in their entirety into this disclosure.
- This invention was made with government support under Grant Nos. HL-10881, HL-067825 and HL-43026 awarded by National Institutes of Health. The United States government has certain rights in the invention.
- Field of the Invention
- The present invention relates to treatment of shock. In particular, the present invention relates to treatment of conditions related to shock.
- Background Information
- Shock is a life-threatening complication in situations associated with trauma including burns, surgery, ischemia, sepsis, and other critical care applications. Shock is a broad term that describes a group of circulatory syndromes, all of which result in general cellular hypoxia. This leads to a depletion of the adenosine triphosphate (ATP), the failure of the sodium-potassium pump, mitochondrial dysfunction, and ultimately the release of a variety of toxic substances, including superoxides. Superoxides are toxic to essentially all tissues. They react with proteins and cause unfolding and are able to induce DNA damage. Additionally, cellular activation in the circulation can be detected by leukocytes or endothelial cells resulting in superoxide production, pseudopod projections, enzyme release, cytokine release, and expression of membrane adhesion molecules. Cell activation fundamentally alters the biomechanics of microvascular blood flow by a shift in rheological, adhesive, and cytotoxic cell properties. Eventually these stress responses give rise to irreversible cardiovascular collapse because of their combined effects on the microcirculation.
- There are few satisfactory drugs, treatment methods, or interventions available for the prevention of conditions related to shock. Most currently available methods for the treatment of such conditions related to shock deal with the symptoms, rather than the cause. For this reason, current clinical approaches are limited in their efficacy and can only prevent further damage from occurring.
- Thus, there is a need in the art for a more effective treatment of conditions related to shock. The treatment should be simple to administer, effective and capable of aiding in emergency situations.
- The present invention is a technique for treatment of conditions related to physiological shock by administering a more specific combination of therapeutic agents, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described methods, for example, that in U.S. Pat. No. 6,534,283, which is incorporated by reference herein in its entirety. The present invention is based upon a new hypothesis for the cause of shock and multi-organ failure: self-digestion through gut ischemic complications rather than bacterial/endotoxin invasion.
- The present invention dramatically reduces symptoms of multi-organ failure and mortality in septic shock associated with leakage of cecal material into the peritoneum (e.g., cecal ligation shock). Furthermore, the present invention reduces symptoms of insulin resistance in shock (e.g., septic, hemorrhagic and cecal ligation shock). The methods were tested and verified in various animal studies as discussed below.
- In experimental models, it was demonstrated that blockade of pancreatic enzymes in the lumen of the intestine in combination with treatment against cytotoxicity in the peritoneum (blockade of digestive enzymes, binding of cytotoxic mediators and anti-bacterial treatment in the peritoneum) leads to a dramatic enhancement of survival rate in a model of septic shock (cecal ligation model).
- In experimental models, it has further been demonstrated that plasma of animals (such as rats) in shock produced by cecal ligation have plasma that exhibits protease activity. The activity is sufficient to cleave the binding domain of insulin on the insulin receptor alpha. Introduction of Futhane and Doxycycline attenuates the insulin receptor cleavage. It is expected that other symptoms of cell and organ dysfunction (such as arterial vasospasm, immune suppression, enhanced permeability, apoptosis, etc.) characteristic for shock will also be attenuated by this treatment.
- Such findings lead to the present invention resulting in treatment techniques for prevention of multi-organ failure and mortality in septic shock associated with leaks from intestine during surgery, punctured intestine, ruptured intestinal legions or appendix, or other any other situation associated with leakage of intestinal material (e.g., cecal or fecal matter). Further, such treatments would lead to prevention of the metabolic syndromes in trauma patients and patients in the ICU.
- In certain exemplary embodiments, the present invention is a method for prevention or treatment of physiological shock. The method includes administering to a peritoneum of an individual a therapeutic dose of any combination of one or more of: pancreatic digestive enzyme inhibitor, cytotoxic mediator inhibitor, and antibacterial agent.
- A method according to the present invention blocks formation of inflammatory mediators by pancreatic digestive enzymes in the intestine in septic shock and thereby reduces symptoms of multi-organ failure and significantly reduces mortality rate. It also serves to reduce morbidity and reduce post-operative complications, enhance recovery rate, and shorten hospital stays.
- The treatment is administered into the lumen of the intestine to block fully activated digestive enzymes and auto-digestion of the intestine. The treatment is highly effective to attenuate prolonged formation of inflammation in septic shock, destruction of the intestinal epithelial lining, and reduces mortality. There is currently no comparable treatment for septic shock.
- This invention describes techniques for treatment of conditions related to shock. Various exemplary embodiments are presented to provide a broad spectrum of treatment available and application to such conditions.
- As discussed above, the strategy for inhibiting gut enteral function has been described in U.S. Pat. No. 6,534,283, which is incorporated by reference herein in its entirety. This patent describes the use of protease inhibition in the lumen of the gut in principle and more specifically using specific commercially available protease inhibitors. The current strategy proposes numerous applications related to pancreatic protease inhibitors.
- In the present invention, treatment is administered into the lumen of the intestine in combination with a treatment of the peritoneal cavity that can be administered after onset of shock.
- In one series of experiments, the inventors discovered that delayed inhibition of digestive enzymes in the lumen of the intestine reduces inflammatory markers after shock. As a clinically relevant situation, the inventors examined the effectiveness of a delayed intestinal protease inhibition during reperfusion after SMAO. Male Wistar rats were exposed to superior mesenteric artery occlusion (SMAO) for 100 min and treated by delayed intestinal lavage beginning 40 min after reperfusion with either buffer or a reversible digestive protease inhibitor (FOY, 0.37 mM). Arterial pressure during reperfusion was significantly lower in shock animals compared with sham shock animals. SMAO and reperfusion without protease blockade caused the formation of leukocyte activation factors in intestinal homogenates and in plasma, as well as intestinal injury and also caused a significant increase in activated leukocytes in venules of cremaster muscle. In contrast, with digestive protease inhibition in the intestine, delayed lavage at 40 min after reperfusion led to a highly significant restoration of the initial blood pressure before shock, decreased formation of intestine-derived leukocyte activation factors and intestinal injury. Delayed digestive enzyme blockade also caused lower leukocytes adhesion in post-capillary venules and reduced cell death in the cremaster muscle microcirculation. Intestinal ischemia-induced endotoxemia was prevented by digestive enzyme inhibition.
- In summary, delayed intestinal protease inhibition serves to improve experimental SMAO-induced shock by reducing intestinal injury, the level of cell activation in plasma and in the microcirculation, and by restoring the blood pressure.
- Another series of experiments were performed to show that inhibition of pancreatic digestive enzymes in the lumen of the intestine reduces the need for resuscitation in hemorrhagic shock. The inventors examined the utility of intestinal lavage in a porcine model of hemorrhagic shock. An objective of this study was to determine the effect of digestive protease blockade in the lumen of the intestine during hemorrhagic shock. The animals (16 pigs) were subjected to a shock that mimics clinical events. Pigs were bled 30 ml/kg over 30 minutes and maintained at a mean arterial pressure of 30 mmHg for 60 minutes and shed blood was then used to maintain a pressure of 45 mmHg for three hours. Both treated pigs (6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate (ANGD), 100 ml/kg of 0.37 mM in GOLYTELY, PEG-3350 and electrolytes for oral solution, via a duodenal catheter at 1 liter/hr directly into the lumen of the intestine) and controls (GOLYTELY, PEG-3350 and electrolytes for oral solution, only) had significant reductions in protein and protease levels in the duodenum during enteroclysis, however only ANGD treated animals had persistent suppression of protease activity in the intestinal lumen and in plasma throughout the experiment. Pigs with blockade of digestive enzymes had a major reduction of transfusion requirement of shed blood (18.1±4.5 ml/kg versus 30±0.43 ml/kg; p=0.002), a significantly lower level of neutrophil activation than controls after resuscitation (31.1±3.3% versus 46.9±4.5% in controls, p=0.0002). Leukocyte infiltration into the lung was lower in treated than control animals (p=0.04) and the liver and small intestine showed less injury in treated animals. In summary, a digestive enzyme inhibitor given via enteroclysis significantly reduces leukocyte activation and transfusion requirements during resuscitation from hemorrhagic shock.
- In another series of studies, the inventors show that blockage of digestive enzymes in the lumen of the intestine attenuates microvascular inflammation in peripheral organs. These experiments were designed to examine whether inflammatory mediators generated in the intestine by digestive enzymes are released early into the circulation and may contribute to the severe systemic inflammatory response syndrome during shock, a condition that involves the microcirculation in peripheral organs. Intestinal ischemia and reperfusion-induced hypotension upon reperfusion was accompanied by a significant increase in the level of neutrophil activating factors in the intestine and plasma. During reperfusion a significant increase in leukocyte-endothelium interactions in post-capillary venules and parenchymal cell death are observed in the cremaster muscle in controls after SMAO. In contrast, intra-intestinal pancreatic protease inhibition (gabexate mesilate, 0.37 mM) results in a stable blood pressure throughout the experiment. Cell activation and leukocyte-endothelial interactions, both in term of rolling and firm adhesion to the endothelium and cell death (as measured by propidium iodine labeling) in the cremaster muscle, were almost completely abolished after blockade with gabexate mesilate. In addition, ischemia-induced intestinal mucosal injury is attenuated with intestinal pancreatic protease inhibition. In conclusion, intestinal pancreatic protease inhibition significantly attenuates intestinal ischemia-induced shock by reducing the systemic inflammatory response syndrome.
- In another series of experiments, the inventors show that digestive enzyme blockade is protective against inflammation in shock if placed inside the lumen of the intestine and less by intravenous administration. From a mechanistic point of view, an important feature is the fact that the significant protection rendered by the inhibition of pancreatic digestive enzymes is only provided if the enzymes are blocked inside the lumen of the intestine. If the enzyme inhibitors are administered directly into the circulation (ib., i.a., i.m.), less, and in some cases no protection is achieved, a feature that has been confirmed using different protease inhibitors (ANGD and aprotinin). This observation supports the hypothesis that digestive enzymes in the lumen of the intestine—where they are fully activated and in high concentrations—are the major enzymes in acute intestinal ischemia. They produce inflammatory mediators that are carried towards the central circulation via the portal venous system, but also via the intestinal lymphatics. Besides the portal venous circulation and the intestinal lymphatics, the inventors showed that inflammatory mediators can also be carried directly across the intestinal wall into the peritoneal cavity, along a third major pathway.
- In another study, the inventors show that digestive enzymes mediate microvascular inflammation in septic shock. Sepsis is accompanied by severe inflammation whose mechanism remains uncertain. The inventors examined the possibility that pancreatic digestive enzymes may also be involved in inflammation in an experimental form of septic shock with a lethal dose of endotoxin in the rat. Immediately after intravenous endotoxin administration, the small intestine was subjected to intra-luminal lavage with and without an inhibitor of pancreatic digestive proteases (FOY, gabexate mesilate). After endotoxin administration (4 mg/kg, gram-negative), control rats developed hypotension, tachycardia, hyperventilation and leukopenia. The intestine and plasma contained mediators that activated leukocytes. The leukocyte-endothelial interaction within the cremaster muscle microcirculation was enhanced. Endotoxin administration resulted in elevated IL-6 plasma levels and histological evidence indicates liver and intestinal injury. In contrast, blockade of pancreatic proteases in the intestinal lumen significantly improved hemodynamic parameters and reduces all indices of inflammation in plasma as well as cell injury in peripheral skeletal muscle microcirculation. These experiments indicate that inflammatory mediators derived from the intestine by digestive proteases may be involved in the prolonged inflammatory response and may sustain symptoms of sepsis after an endotoxin challenge. A bolus administration of endotoxin causes a transient inflammation response and elevated intestinal permeability. But the sustained inflammation that leads to multi-organ failure in this situation is caused by auto-digestion due to escape of pancreatic digestive enzymes from the lumen of the intestine due to the elevated mucosal permeability.
- A study of the long term survival after blockade of digestive enzymes provided further support to the findings. In preparation for this application the inventors carried out pilot studies in the rat with (a) hemorrhagic, (b) endotoxic and (c) cecal ligation shock, followed by an observation period for two weeks until normal cage activities were recorded in survivors. Without food restriction, in hemorrhagic shock the mean blood pressure was reduced for two hours to 35 mmHg followed by return of all blood volume but no further resuscitation. The digestive enzymes were blocked at 1 hour after hypotension by direct infusion of ANGD (0.37 mM, 15 ml) into the intestinal lumen after a temporary exposure via a midline incision. In endotoxic shock, the rats received gram-negative endotoxin (5 mg/kg, ib.); the digestive enzymes were blocked in the same way at 1 hour after endotoxin administration. No other agent was administered. In cecal ligation shock both the digestive enzymes in the lumen of the intestine as well as inside the peritoneum were blocked with ANGD. Untreated controls in each model of shock had high mortality (within less than 8 hours), while blockade of the digestive enzymes ANGD in each shock model lead to a significantly enhanced survival rate (Table I). In contrast to untreated controls, all treated survivors returned after anesthesia within hours to normal activity (walking, climbing, grooming, drinking, eating, bowel movements) and within 3 days to normal weight gain. Furthermore, treatment with alternative serine protease inhibitors (CYCLOKAPRON, tranexamic acid; TRASYLOL, aprotinin) in cecal ligation shock gave significant survival rates (5/5 rats, P<0.0079; 4/5 rats, P<0.02, respectively).
-
TABLE I Long-Term Survival Following Shock With and Without Intra-Intestinal Enzyme Blockade* (A) Hemorrhagic (B) Endotoxic (C) Cecal Lig. Shock1 Shock2 Shock3 Non- Non- Non- Survivor Survivor Survivor Survivor Survivor Survivor Untreated 9 3 9 4 9 1 ANGD 2 10 1 10 1 9 Treated *number of rats 1P < 0.01 2P < 0.004 3P < 0.001 by Fisher's Exact Test - It was further shown that plasma of shock rats has protease activity and causes cleavage of the extracellular domain of the insulin receptor, E-cadherin, and CAT-1. In all forms of shock there is consistently proteolytic activity in plasma. Therefore the inventors investigated the ability of central venous plasma of rats in hemorrhagic shock (collected at 4 hours) to cleave the extracellular domain of the insulin receptor a by using an antibody against the extracellular binding domain of insulin combined with membrane receptor density measurements. Exposure of normal donor cells to plasma from shock rats, but not to plasma of control rats, causes extensive cleavage of the insulin binding domain. Furthermore, this cleavage causes also a reduction of the glucose transport into the cell cytoplasm. These results show that the plasma enzymatic activity may be responsible for the development of insulin resistance typical for patients in shock. The activity can be significantly blocked with ANGD (by more than 50%, results not shown), suggesting that proteases are a major component of this enzyme activity. There is also a significant cleavage of the extracellular domain of the tight junction protein E-cadherin in intestinal epithelium and CAT-1 in leukocytes.
- Another recent study by the inventors, listed as item (9) below, and which is incorporated by reference herein in its entirety, showed that pancreatic enzymes generate cytotoxic mediators in the intestine. And, thus, there exists a link between the permeability increase in the intestinal wall and the early stages of shock with formation of inflammatory and cytotoxic factors. These factors may either be already present in form of digested food or may be created by action of digestive enzymes on interstitial structures after entry into the intestinal wall and may cause the intestinal necrosis observed in shock. We have shown that both individual serine proteases and fluid from the lumen of the intestine with endogenous proteases have the ability to generate cytotoxicity from intestinal wall homogenates and that luminal fluid may also generate cytotoxicity from homogenized food. These findings further support the hypothesis that lavage of the content of the small intestine with broad-spectrum inhibitors may be protective in shock, in line with experimental evidence. There is a need to identify the actual biochemical structure of the cytotoxic factors and determine their mechanism of action.
- In another follow up study, listed as item (10) below and incorporated by reference herein in its entirety, the inventors sought to show that the intestine is a source of cytotoxic mediators in shock, and the role of free fatty acids and degradation of lipid-binding proteins. In this study, the inventors showed that using chloroform/methanol separation of rat small intestine homogenates into lipid fractions and aqueous and sedimented protein fractions and measuring cell death caused by those fractions, it was found that the cytotoxic factors are lipid in nature. Recombining the lipid fraction with protein fractions prevented cell death, except when homogenates were protease digested. Using a fluorescent substrate, the inventors found high levels of lipase activity in intestinal homogenates and cytotoxic levels of free fatty acids. Addition of albumin, a lipid binding protein, prevented cell death, unless the albumin was previously digested with protease. Homogenization of intestinal wall in the presence of the lipase inhibitor orlistat prevented cell death after protease digestion. In vivo, orlistat plus the protease inhibitor aprotinin, administered to the intestinal lumen, significantly improved survival time compared with saline in a splanchnic arterial occlusion model of shock. These results indicate that major cytotoxic mediators derived from an intestine under in vitro conditions are free fatty acids (FFAs). Breakdown of free fatty acid binding proteins by proteases causes release of free fatty acids to act as powerful cytotoxic mediators.
- The discovery further includes clarification of the mechanism that leads to insulin resistance. It is shown that one of the ways that the present invention works is due to enzymatic cleavage of the insulin binding-domain, and introduction of proteases attenuates the process.
- There is currently no generally accepted treatment algorithm or protocol for treatment of insulin resistance in shock. Limited options include insulin administration.
- In another recent study, listed as item (11) below and incorporated by reference herein in its entirety, the inventors showed that there is a relationship between proteinase activity and receptor cleavage and that there appears to be a mechanism for insulin resistance in the spontaneously hypertensive rat. The inventors hypothesized that enhanced proteolytic activity in the microcirculation of spontaneously hypertensive rats (SHRs) may be a pathophysiological mechanism causing cell membrane receptor cleavage and examined this for 2 different receptors. Immunohistochemistry of matrix-degrading metalloproteinases (matrix metalloproteinase (MMP)-9) protein showed enhanced levels in SHR microvessels, mast cells, and leukocytes compared with normotensive Wistar-Kyoto rats. In vivo microzymography shows cleavage by MMP-1 and -9 in SHRs that colocalizes with MMP-9 and is blocked by metal chelation. SHR plasma also has enhanced protease activity. The inventors demonstrated with an antibody against the extracellular domain that the insulin receptor-α density is reduced in SHRs, in line with elevated blood glucose levels and glycohemoglobin. There is also cleavage of the binding domain of the leukocyte integrin receptor CD 18 in line with previously reported reduced leukocyte adhesion. Blockade of MMPs with a broad-acting inhibitor (doxycycline, 5.4 mg/kg per day) reduces protease activity in plasma and microvessels; blocks the proteolytic cleavage of the insulin receptor, the reduced glucose transport; normalizes blood glucose levels and glycohemoglobin levels; and reduces blood pressure and enhanced microvascular oxidative stress of SHRs. The results suggest that elevated MMP activity leads to proteolytic cleavage of membrane receptors in the SHR, e.g., cleavage of the insulin receptor-binding domain associated with insulin resistance.
- Further, there is currently no generally accepted treatment algorithm or protocol for septic shock. There is an FDA approved treatment with activated protein C (XIGRIS, drotrecogin alfa (activated), Eli Lilly), which gives a minor but confirmed survival benefit. However, even such treatment has been called into question as more recent trials could not confirm the effectiveness of activated protein C.
- Treatment of septic shock is based on supportive care by treating the underlying infection (appropriate antibiotics within the first 4-8 hours of presentation) and on restoring tissue perfusion with a combination of fluid resuscitation (e.g., albumin, lactated or hypertonic saline) and vasopressor administration (e.g., noreinephrine).
- In an exemplary embodiment, the present invention involves several components, which may be performed independently or in combination. One component of a treatment according to the present invention includes administration of a pancreatic enzyme inhibitor directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery, etc.). The agents to be used individually or in combination include but are not limited to: FUTHAN, nafamostat mesilate (0.37 mM); TRASYLOL, aprotinin (Aprotinin, Bayer) (1.4 mg/ml), serine protease inhibitor; CYKLOKAPRON, tranexamic acid (Pfizer) (1.4 mg/ml), serine protease inhibitor; broad based MMP inhibitors (e.g., doxycycline); orlistat (5 to 50 mg/ml), lipase inhibitor; plus any other pancreatic enzyme inhibitor. The amount administered may be adjusted according to intestine size and enzyme levels to achieve complete blockade of digestive enzyme activity.
- A second component of a treatment according to the present invention includes treatment of the peritoneum by a combination of three protective interventions: blockade of pancreatic digestive enzymes (serine proteases, lipases, as outlined in the first component described above); blockade of cytotoxic lipid derived mediators (e.g., free fatty acids) with free fatty acid binding proteins (e.g., albumin, and others); antibacterial treatment against gram-positive and gram-negative bacteria that have entered into the peritoneal space (with antibiotic treatment, e.g., ciprofloxacin, metronidazole, imipenem and cilastatin, ticarcillin and clavulanate, cefuroxime). Further effectiveness of the treatment is achieved by peritoneal/intraintestinal lavage in combination with the treatments listed above.
- The administration of the serine proteases and MMPs with broad spectrum blockers, as outlined in the first component described above, may be alternatively or additionally performed through an intravenous (ib.) route.
- The present invention may be used in numerous medical treatments, including but not limited to, treatment for prevention of multi-organ failure and mortality in septic shock. Any lipase inhibitor in combination with a pancreatic or leukocyte derived protease inhibitor may have utility to prevent inflammation in septic shock.
- In one exemplary embodiment, which may be used for treatment for prevention of post-operational complications, including multi-organ failure, sepsis, morbidity, and mortality, pancreatic protease inhibition is initiated to reduce complications and hospital stay after trauma/surgery. Here, it has been shown that pancreatic enzymes in the intestine have the ability to generate powerful inflammatory mediators and that blockade of pancreatic enzymes in the lumen of the intestine attenuates inflammatory symptoms after different shock models.
- In this embodiment, the present invention allows a reduction in inflammatory symptoms and complications (swelling, embolism formation, selected organ dysfunction, pulmonary embolism, incidence of stroke, patient mobility, morbidity, multi-organ failure, mortality) in any form of elective surgery/general anesthesia associated with elevated risks (such as prolonged surgery procedures, surgery with bypass requirements, surgery on patients with preconditions and risk factors, surgery involving the intestine and pancreas). This results in a reduction in post-surgical complications, enhance wound healing, reduce total recovery period, and reduce hospitalization requirements and time.
- In elective surgery, pre-administration of a pancreatic enzyme inhibitor may be conducted directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery). The agents to be used are individually or in combination: Futhane (0.1 mM); Trasylol (Aprotinin, Bayer) (1.4 mg/ml), serine protease inhibitor; cyclokapron (Pfizer) (1.4 mg/ml), serine protease inhibitor; Orlestat (5 to 50 mg/ml), lipase inhibitor plus any other pancreatic enzyme inhibitor. The amount administered is adjusted according to intestine size to achieve complete blockade of digestive enzyme activity. The inhibitor is administered prior to general anesthesia/surgery as pretreatment.
- This is the first intervention against a major source of inflammation in multi-organ failure associated with surgery/general anesthesia. Blockade of digestive enzymes prior to general anesthesia may serve to preserve barrier properties of the intestinal mucosa, reduce inflammation in the central circulation, and consequently reduce recovery and wound healing periods, post-surgical complications, hospital stays, etc.
- A potentially useful application of the digestive enzyme inhibition as pre-treatment is for patients subjected to radiation or chemotherapeutic treatment. It could also work for radiation treatment under other circumstances to reduce symptoms of multi-organ failure.
- In another exemplary embodiment, the present invention provides a method for pancreatic protease inhibition in septic shock. There are many uses for this embodiment, including but not limited to, treatment for prevention of multi-organ failure and mortality in septic shock. Such treatment works by blocking formation of inflammatory mediators by pancreatic digestive enzymes in the intestine in septic shock and thereby reducing symptoms of multi-organ failure and mortality.
- The treatment is administered into the lumen of the intestine to block fully activated digestive enzymes and auto-digestion of the intestine. The treatment is highly effective to attenuate prolonged formation of inflammation in septic shock, destruction of the intestinal epithelial lining, and reduces mortality.
- It is demonstrated that blockade of pancreatic enzymes in the lumen of the intestine attenuates inflammatory symptoms after administration of a lethal dose of endotoxin (6 mg/kg). Experiments demonstrate reduced long-term mortality in the same sepsis model.
- Administration of a pancreatic enzyme inhibitor may be conducted directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery). The agents to be used are individually or in combination: FUTHAN, nafamostat mesilate (0.1 mM); TRASYLOL, aprotinin (1.4 mg/ml), serine protease inhibitor; orlistat (5 to 50 mg/ml), lipase inhibitor; plus any other pancreatic enzyme inhibitor. The amount administered is adjusted according to intestine size to achieve complete blockade of digestive enzyme activity.
- In another exemplary embodiment, the present invention is used for pancreatic lipase inhibition to reduce mortality after shock. This embodiment is very useful for developing treatment for prevention of multi-organ failure and mortality in hemorrhagic shock, preventive treatment to reduce the probability for development of multi-organ failure in elective surgery, long-term treatment to reduce production of lipid derived inflammatory mediators associated in chronic diseases. It is also particularly useful because there does not appear to be any treatment proposed to attenuate inflammation by blockade of lipase activity in the intestine in either acute or chronic inflammatory conditions.
- This embodiment is designed as an intervention to block the lipase activity in the lumen of the intestine and also in the general circulation in those cases in which lipase enters from the lumen of the intestine into the circulation. This prevents formation of lipid derived inflammatory or cytotoxic mediators in shock and other inflammatory diseases and attenuate multi-organ failure in shock and chronic inflammation in diseases like hypertension, diabetes, the metabolic syndrome, cancers and in chronic degenerative diseases.
- Recent evidence resulting in this invention suggests that a major component of inflammatory mediators from the intestine in shock causing multi-organ failure and mortality (e.g., after surgery/general anesthesia, trauma, chronic diseases and any other condition leading multi-organ failure) is derived from the action of pancreatic lipases (lipid splitting enzymes). Blockade of pancreatic lipase serves to reduce mortality during shock and reduce inflammation that leads to multi-organ failure. Blockade of pancreatic lipase prior to general anesthesia may serve to preserve barrier properties of the intestinal mucosa, reduce inflammation in the central circulation, and consequently reduce recovery and wound healing periods, post-surgical complications, hospital stays, etc.
- The inventors have shown that the ischemic intestine produces a powerful set of lipid derived cytotoxic mediators and that the blockade of lipase in the intestine under in-vitro conditions blocks the production of lipid-derived cytotoxic mediators.
- In elective surgery, pre-administration of a pancreatic enzyme inhibitor directly into the lumen of the intestine (by oral administration, introduction via an esophageal catheter, direct injection into the lumen of the intestine during surgery) may have a positive effect on recovery. The agents to be used are individually or in combination: orlistat (5 to 50 mg/ml), lipase inhibitor; plus any other pancreatic enzyme inhibitor. The amount administered is adjusted according to intestine size and content to achieve complete blockade of digestive enzyme activity. As treatment the inhibitor is administered after trauma or sepsis associated with risk for shock and multi-organ failure. As pretreatment the inhibitor is administered prior to general anesthesia/surgery.
- The above exemplary embodiments have shown various uses and techniques for decreasing certain conditions related to shock. Thus, as a whole, the present invention is based on data from animal studies that show dramatic reduction in life-threatening shock by inhibiting a body's own aggressive digestive enzymes. This novel approach targets trigger mechanisms in auto-digestion before it launches lethal inflammatory cascade.
- Death from heart, lung and kidney failure during shock due to inadequate blood flow can be prevented by an unusual experimental treatment that inhibits the aggressive enzymes that are produced in body to digest food.
- The invention provides evidence from recent animal studies that for the first time, studies showed that blockade of the digestive enzymes during shock leads to long-term survival. The results show a dramatic reduction of mortality in hemorrhagic shock induced multi-organ failure. This treatment holds great promise for future clinical application, particularly in emergency rooms and before high-risk surgeries. When a person is in shock, his or her life is on the line. The patient's survival may be in jeopardy not just that day, but within an hour because healthy organs can fail and die in rapid succession.
- An estimated 1 million cases of various types of shock are treated annually in U.S. hospital emergency rooms. Shock is a serious medical condition with a fatality rate of approximately 29%. While the optimal management of shock patients can improve survival rates, overall shock remains a condition with a high death rate.
- Administering a drug to inhibit the body's digestive enzymes is a relatively new approach that was begun in the past decade. In 1998 a finding was made in laboratory studies on the body's inflammatory cascade and the factors that turn this normal tissue-healing biological process into a virulent, out of control firestorm against the body's normal tissue.
- The researchers then began animal studies. The present invention is based on the latest research using rodent models of human hemorrhagic shock. Here it has been discovered that the sudden lowering of blood pressure that occurs in people suffering from stroke can provoke the body's digestive enzymes to break down the body's own intestinal tissue as if it were food. Such enzymes' abnormal actions may be defined as “auto-digestion.” Auto-digestion is dangerous because not only does it injure healthy tissue but also contributes to multi-organ failure, which can be fatal.
- The healthy cells of the animals' intestinal tissue react to auto-digestion by releasing a slew of substances that can be toxic to the heart and other body organs. These substances, termed cytotoxic mediators, can reach these body organs via the blood stream. In their latest studies, shock was induced in 19 lab rodents, all of which were then treated with therapies that mirror the emergency room care given to many human patients who suffer shock, which typically occurs when blood flow to the heart, lungs and other body organs is slowed as a result of trauma, dehydration, heart attack or stroke.
- A total of 10 of the 19 lab rodents in shock were also treated with the experimental digestive enzyme inhibitor called ANGD. Eight of the ten survived. However, only one of the nine “untreated” animals in shock survived. The other eight animals died from organ failure within 12 hours. Although these “untreated” animals did not receive ANGD, the inhibitor, they were given basic shock care. The enzyme inhibitor ANGD dramatically improved the survival rate among the lab animals in which shock had been induced.
- In the pig studies, the scientists also are conducting experiments to identify the time period when the experimental treatment will be the most effective in saving lives. The findings will be relevant to the emergency care of human patients in shock. Data indicate that the earlier the treatment occurs, the better the chances for survival. Current research indicates that the window of opportunity for the treatment to be effective does not seem to be very narrow.
- The discovery of the “auto-digestion” process and their positive findings from the experimental treatment ANGD are based on National Institutes of Health funded basic research to determine the origin of the inflammatory cascade that causes organ failure and death. Basically, inflammatory is the body's mechanism to repair, to heal tissue. But in shock, the inflammation never stops. It is out of control. Normally the body senses when the inflammatory process has completed its job and brings it to a halt.
- There is little surprise that tissue can be severely damaged by the actions the body's digestive enzymes, which are secreted by the pancreas but do not become activated until they arrive into the intestines. Digestive enzymes have to be very aggressive, and there has to be lots of them, for the body to efficiently digest, to break down, the food that we eat. Normally the intestinal tissue is protected from these enzymes by a layer of secreted mucus and by the tight packing of the cells in the intestinal wall. The enzymes are too big to defuse between these cells under normal conditions.
- The following references, some as cited above, are hereby incorporated by reference herein in their entirety into this disclosure:
- 1. Schmid-Schonbein G W, Hugli T E. A New Hypothesis for Microvascular Inflammation in Shock and Multi-organ Failure: Self-Digestion by Pancreatic Enzymes. Microcirculation. 2005; 12:71-82.
- 2. Doucet J J, Hoyt D B, Coimbra R, et al. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock. J Trauma. 2004; 56:501-511.
- 3. Fitzal F, DeLano F A, Young C, Schmid-Schonbein G W. Improvement in early symptoms of shock by delayed intestinal protease inhibition. Arch Surg. 2004; 139:1008-1016.
- 4. Deitch E A, Shi H P, Lu Q, et al. Serine proteases are involved in the pathogenesis of trauma-hemorrhagic shock-induced gut and lung injury. Shock. 2003; 19:452-456.
- 5. Shi H P, Liu Z J, Wen Y. Pancreatic enzymes in the gut contributing to lung injury after trauma/hemorrhagic shock. Chin J Traumatol. 2004; 7:36-41.
- 6. Muhs B E, Patel S, Yee H, et al. Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis. J Surg Res. 2003; 109:110-7.
- 7. Rosario H S, Waldo S W, Becker S A, et al. Pancreatic trypsin increases matrix metalloproteinase-9 accumulation and activation during acute intestinal ischemia-reperfusion in the rat. Am J Pathol. 2004; 164:1707-16.
- 8. Fitzal F, DeLano F A, Young C, Rosario H S, Junger W G, Schmid-Schonbein G W. Pancreatic enzymes sustain systemic inflammation after an initial endotoxin challenge. Surgery, 134:446-456, 2003.
- 9. Penn, A H, Hugli, T E, Schmid-Schonbein, G W. Pancreatic enzymes generate cytotoxic mediators in the intestine. Shock, Vol. 27, No. 3, pp. 296-304, 2007.
- 10. Penn, A H, Schmid-Schonbein, G W. The intestine as source of cytotoxic mediators in shock: free fatty acids and degradation of lipid binding proteins. Am J Physiol Heart Circ Physiol 294: H1779-H1792, 2008.
- 11. DeLano, F A, Schmid-Schonbein, G W. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008; 52:415-423.
- The foregoing disclosure of the preferred embodiments of the present invention has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise forms disclosed. Many variations and modifications of the embodiments described herein will be apparent to one of ordinary skill in the art in light of the above disclosure. The scope of the invention is to be defined only by the claims appended hereto, and by their equivalents.
- Further, in describing representative embodiments of the present invention, the specification may have presented the method and/or process of the present invention as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. As one of ordinary skill in the art would appreciate, other sequences of steps may be possible. Therefore, the particular order of the steps set forth in the specification should not be construed as limitations on the claims. In addition, the claims directed to the method and/or process of the present invention should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the present invention.
Claims (19)
1. A method for treating or preventing septic shock in an individual in need thereof, the method comprising administering to a peritoneum of the individual a therapeutic dose of: (i) a pancreatic digestive enzyme inhibitor, (ii) a cytotoxic mediator inhibitor, (iii) an antibacterial agent, or (iv) a combination of two or more thereof.
2. The method of claim 1 , further comprising administering to the individual a therapeutic dose of an MMP inhibitor.
3. The method of claim 1 , wherein the MMP inhibitor is doxycycline.
4. The method of claim 1 , further comprising administering to an intestine of the individual a therapeutic dose of: (i) a serine protease inhibitor, (ii) a lipase inhibitor, or (iii) a combination thereof.
5. The method of claim 1 , comprising administering the pancreatic digestive enzyme inhibitor.
6. The method of claim 5 , wherein the pancreatic digestive enzyme inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, orlistat, or a combination of two or more thereof.
7. The method of claim 6 , wherein the pancreatic digestive enzyme inhibitor is tranexamic acid.
8. A method for treating or preventing septic shock in an individual in need thereof, the method comprising administering into a lumen of an intestine of the individual a therapeutic dose of a serine protease inhibitor.
9. The method of claim 8 , wherein the serine protease inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, or 6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate.
10. The method of claim 9 , wherein the serine protease inhibitor is tranexamic acid.
11. The method of claim 8 , wherein administering into a lumen of an intestine comprises oral administration, introduction via an esophageal catheter, or direct injection into the lumen of the intestine.
12. The method of claim 8 , further comprising administering to the peritoneal cavity of the individual a therapeutic dose of a pancreatic digestive enzyme inhibitor.
13. The method of claim 12 , wherein the pancreatic digestive enzyme inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, orlistat, or a combination of two or more thereof.
14. The method of claim 12 , wherein the pancreatic digestive enzyme inhibitor is a serine protease inhibitor.
15. The method of claim 14 , wherein the serine protease inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, or 6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate.
16. The method of claim 15 , wherein the serine protease inhibitor is tranexamic acid.
17. A method for treating or preventing septic shock in an individual in need thereof, the method comprising administering to the peritoneum of the individual a therapeutic dose of a serine protease inhibitor.
18. The method of claim 17 , wherein the serine protease inhibitor is nafamostat mesilate, aprotinin, tranexamic acid, or 6-amidino-2-naphthyl p-guanidobenzoate dimethane-sulfate.
19. The method of claim 18 , wherein the serine protease inhibitor is tranexamic acid.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/404,002 US20170119710A1 (en) | 2007-10-04 | 2017-01-11 | Treatment of conditions related to shock |
US15/890,108 US20180153834A1 (en) | 2007-10-04 | 2018-02-06 | Treatment of conditions related to shock |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97758707P | 2007-10-04 | 2007-10-04 | |
US98043007P | 2007-10-16 | 2007-10-16 | |
PCT/US2008/011529 WO2009045543A1 (en) | 2007-10-04 | 2008-10-06 | Treatment of conditions related to shock |
US68151010A | 2010-08-09 | 2010-08-09 | |
US15/010,058 US20160144007A1 (en) | 2007-10-04 | 2016-01-29 | Treatment of conditions related to shock |
US15/404,002 US20170119710A1 (en) | 2007-10-04 | 2017-01-11 | Treatment of conditions related to shock |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/010,058 Continuation US20160144007A1 (en) | 2007-10-04 | 2016-01-29 | Treatment of conditions related to shock |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/890,108 Continuation US20180153834A1 (en) | 2007-10-04 | 2018-02-06 | Treatment of conditions related to shock |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170119710A1 true US20170119710A1 (en) | 2017-05-04 |
Family
ID=40526587
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/681,510 Active 2030-08-21 US9272034B2 (en) | 2007-10-04 | 2008-10-06 | Treatment of conditions related to shock |
US15/010,058 Abandoned US20160144007A1 (en) | 2007-10-04 | 2016-01-29 | Treatment of conditions related to shock |
US15/404,002 Abandoned US20170119710A1 (en) | 2007-10-04 | 2017-01-11 | Treatment of conditions related to shock |
US15/890,108 Abandoned US20180153834A1 (en) | 2007-10-04 | 2018-02-06 | Treatment of conditions related to shock |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/681,510 Active 2030-08-21 US9272034B2 (en) | 2007-10-04 | 2008-10-06 | Treatment of conditions related to shock |
US15/010,058 Abandoned US20160144007A1 (en) | 2007-10-04 | 2016-01-29 | Treatment of conditions related to shock |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/890,108 Abandoned US20180153834A1 (en) | 2007-10-04 | 2018-02-06 | Treatment of conditions related to shock |
Country Status (2)
Country | Link |
---|---|
US (4) | US9272034B2 (en) |
WO (1) | WO2009045543A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9272034B2 (en) | 2007-10-04 | 2016-03-01 | The Regents Of The University Of California | Treatment of conditions related to shock |
US8338127B2 (en) | 2008-01-31 | 2012-12-25 | Anazyme | Testing a mammal for presence, progression or stage of a shock condition |
US8541371B2 (en) | 2008-04-22 | 2013-09-24 | The Regents Of The University Of California | Treatment of conditions related to cecal ligation shock |
CN102597767A (en) * | 2009-09-18 | 2012-07-18 | 加利福尼亚大学董事会 | Methods for detecting autodigestion |
WO2011038417A2 (en) | 2009-09-28 | 2011-03-31 | The Regents Of The University Of California | Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation |
EP3677261B8 (en) * | 2010-09-23 | 2023-07-19 | Leading BioSciences, Inc. | Administration of serine protease inhibitors to the stomach |
KR20140091460A (en) | 2010-10-02 | 2014-07-21 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Minimizing intestinal dysfunction |
US9354933B2 (en) * | 2011-10-31 | 2016-05-31 | Intel Corporation | Remote direct memory access adapter state migration in a virtual environment |
CN112641771B (en) | 2014-03-25 | 2022-04-15 | 恒翼生物医药科技(上海)有限公司 | Composition for treating autodigestion |
US11202768B2 (en) | 2016-01-11 | 2021-12-21 | Leading BioSciences, Inc. | Compositions and methods for treating and preventing adhesions and ileus |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193507A1 (en) * | 2004-02-13 | 2008-08-14 | Paul Kemp | Wound Healing Profile |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171321A (en) | 1992-03-09 | 1992-12-15 | Davis Joseph P | Nipple prosthesis and method of making the same |
JPH0731829A (en) | 1993-06-28 | 1995-02-03 | Dainippon Printing Co Ltd | Carbon dioxide absorbing sheet |
US5743272A (en) | 1996-04-10 | 1998-04-28 | Kocher, Jr.; Robert W. | Male nipple abrasion protector |
US5993427A (en) * | 1996-12-03 | 1999-11-30 | Laborie Medical Technologies Corp. | Everting tube structure |
US6168779B1 (en) | 1997-09-16 | 2001-01-02 | The Regents Of The University Of California | Methods and kits for identifying ductal orifices |
CN1299286A (en) | 1998-04-01 | 2001-06-13 | 澳洲生物科技公司 | Use of protease inhibitors for treating skin wounds |
IL128380A0 (en) | 1999-02-04 | 2000-01-31 | Yeda Res & Dev | A method of screening for agonists and antagonists of FGFR |
DE60031114T2 (en) | 1999-06-11 | 2007-05-03 | Cytyc Corp., Marlborough | LIQUID GEL FORMULATION FOR DETECTING MILK CHANNELS IN THE CHEST BEFORE SURGICAL ABLATION OF THE BREAST TISSUE |
US6534283B1 (en) | 1999-11-24 | 2003-03-18 | The Regents Of The University Of California | Method for treatment and prevention of physiological shock |
WO2001058491A1 (en) | 2000-02-10 | 2001-08-16 | Takeda Chemical Industries, Ltd. | Drug comprising combination |
US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
AU2001266779A1 (en) | 2000-06-08 | 2001-12-17 | Cytyc Health Corporation | Preparation for breast duct fluid collection |
US6610274B1 (en) | 2000-12-22 | 2003-08-26 | Wallace J. Gardner | Anti-inflammatory composition comprising tetracycline |
US20020117169A1 (en) | 2001-02-27 | 2002-08-29 | Kurz Daniel R. | Cover and applicator for a portion of a mammalian body |
UY27304A1 (en) * | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | INHIBITORS OF THE INHIBITOR FACTOR OF MIGRATION OF MACROPHAGES AND METHODS FOR IDENTIFICATION |
WO2003030821A2 (en) * | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
GB2400037A (en) | 2003-03-31 | 2004-10-06 | Psimedica Ltd | Device made of silicon and method for collecting mammary fluid |
US20060216757A1 (en) * | 2003-04-25 | 2006-09-28 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex, assays for identifying tissue protective compounds and uses thereof |
GB2408207A (en) | 2003-11-24 | 2005-05-25 | Johnson & Johnson Medical Ltd | Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme & a linker group cleavable by such an enzyme |
US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
US7368529B2 (en) * | 2004-03-30 | 2008-05-06 | Reliance Life Science Pvt. Ltd. | Agent and compositions comprising the same for inhibiting lipases and phospholipases in body fluids, cells and tissues |
EP1768647B1 (en) * | 2004-06-17 | 2012-08-08 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agent |
SE0402025D0 (en) | 2004-08-13 | 2004-08-13 | Active Biotech Ab | Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent |
KR20070073863A (en) * | 2004-10-04 | 2007-07-10 | 트리니티 바이오시스템스, 인크. | Methods and compositions for needleless delivery of macromolecules |
US20070292407A1 (en) | 2005-12-12 | 2007-12-20 | The Board Of Trustees Operating Michigan State University | Methods of treatment for meconium aspiration syndrome |
US20070142337A1 (en) | 2005-12-15 | 2007-06-21 | The Regents Of The University Of California | Treatment of inflammation and organ dysfunction |
WO2008103767A1 (en) | 2007-02-20 | 2008-08-28 | The Regents Of The University Of California | Treatment of conditions related to shock |
US9272034B2 (en) | 2007-10-04 | 2016-03-01 | The Regents Of The University Of California | Treatment of conditions related to shock |
US8541371B2 (en) | 2008-04-22 | 2013-09-24 | The Regents Of The University Of California | Treatment of conditions related to cecal ligation shock |
WO2011038417A2 (en) | 2009-09-28 | 2011-03-31 | The Regents Of The University Of California | Methods to accelerate tissue and wound healing rates and reduce swelling and scar formation |
WO2011088392A2 (en) | 2010-01-14 | 2011-07-21 | The Regents Of The University Of California | Devices, systems and methods to detect and reduce or prevent entry of inflammatory mediators into milk ducts |
KR20140091460A (en) | 2010-10-02 | 2014-07-21 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Minimizing intestinal dysfunction |
-
2008
- 2008-10-06 US US12/681,510 patent/US9272034B2/en active Active
- 2008-10-06 WO PCT/US2008/011529 patent/WO2009045543A1/en active Application Filing
-
2016
- 2016-01-29 US US15/010,058 patent/US20160144007A1/en not_active Abandoned
-
2017
- 2017-01-11 US US15/404,002 patent/US20170119710A1/en not_active Abandoned
-
2018
- 2018-02-06 US US15/890,108 patent/US20180153834A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193507A1 (en) * | 2004-02-13 | 2008-08-14 | Paul Kemp | Wound Healing Profile |
Also Published As
Publication number | Publication date |
---|---|
US20160144007A1 (en) | 2016-05-26 |
US20180153834A1 (en) | 2018-06-07 |
US9272034B2 (en) | 2016-03-01 |
US20100303799A1 (en) | 2010-12-02 |
WO2009045543A8 (en) | 2009-08-27 |
WO2009045543A1 (en) | 2009-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9272034B2 (en) | Treatment of conditions related to shock | |
US8541371B2 (en) | Treatment of conditions related to cecal ligation shock | |
US11439611B2 (en) | Administration of serine protease inhibitors to the stomach | |
Pawlik et al. | Nitric oxide (NO)-releasing aspirin exhibits a potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines | |
US20100179091A1 (en) | Treatment of Conditions Related to Shock | |
MXPA03010493A (en) | Use of sulodexide for the treatment of inflammatory bowel disease. | |
US20110245149A1 (en) | Methods to prevent and treat diseases | |
Xue et al. | Etanercept attenuates short-term cigarette-smoke-exposure-induced pulmonary arterial remodelling in rats by suppressing the activation of TNF-α/NF-κB signal and the activities of MMP-2 and MMP-9 | |
Li et al. | Direct cardiac actions of sodium-glucose cotransporter 2 inhibition improve mitochondrial function and attenuate oxidative stress in pressure overload-induced heart failure | |
Zou et al. | The role of neutrophil extracellular traps in sepsis and sepsis-related acute lung injury | |
Walensi et al. | Mesenteric ischemia-reperfusion injury: Clearly improved hemodynamics but only minor protection of the rat small intestine by (sub) therapeutic heparin sodium and enoxaparin doses | |
Köksoy et al. | Preventive effects of enoxaparin and hesperidin in cerulein-induced acute pancreatitis in rats | |
JP2022530732A (en) | Compounds for treating and preventing NET-related complications | |
Wu et al. | Eriocitrin prevents Sepsis-induced acute kidney injury through anti-inflammation and anti-oxidation via modulating Nrf2/DRP1/OPA1 signaling pathway | |
Guven | Reducing effects of ginkgo biloba (egb761) extract on skeletal muscle ischemia-reperfusion injury in rats | |
Ahn et al. | A leukocyte elastase inhibitor reduces thrombin-induced pulmonary oedema in the rat: mechanisms of action | |
RU2563796C1 (en) | Method of treating ischemic hepatic injuries | |
Smith | Pharmacological treatment in venous leg ulcers | |
RU2403911C1 (en) | Agent for increasing survival rate in acute blood loss | |
Mehmet Guler et al. | Efficiency of Ankaferd Blood Stopper Used in Bleeding Control on Intraabdominal Adhesions Formed Postoperatively | |
Ellger et al. | Normoglycemia and not glycemia-independent actions of insulin maintain physiologic NOS-activity by preserving physiological regulation of ADMA-levels: 12AP4-3 | |
Rowe | Detection of apoptotic cells in horses with and without gastrointestinal disease | |
PAWLIK et al. | M. MAZURKIEWICZ-JANIK, SJ KONTUREK, WW PAWLIK, T. BRZOZOWSKI NITRIC OXIDE (NO)-RELEASING ASPIRIN EXHIBITS A POTENT ESOPHAGOPROTECTION IN EXPERIMENTAL MODEL OF ACUTE REFLUX ESOPHAGITIS. ROLE OF NITRIC OXIDE AND PROINFLAMMATORY CYTOKINES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHMID-SCHONBEIN, GEERT W.;DELANO, FRANK A.;SIGNING DATES FROM 20080724 TO 20080805;REEL/FRAME:044192/0132 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |